The advent of mRNA vaccines against SARS-CoV-2 in 2020 changed the course of the COVID-19 pandemic. Now, the Nobel ...
Add Yahoo as a preferred source to see more of our stories on Google. The United States is turning its back on what could be the greatest medical advance in a generation — vaccines made with messenger ...
The U.S. FDA has granted Fast Track designation for mRNA-4359 in combination with pembrolizumab for the treatment of ...
Add Yahoo as a preferred source to see more of our stories on Google. Health and Human Services Secretary Robert F. Kennedy Jr. canceled $500 million of funding for research on mRNA vaccine technology ...
EDITOR’S NOTE: The views expressed in this commentary are solely those of the writer. CNN is showcasing the work of The Conversation, a collaboration between journalists and academics to provide news ...
Messenger RNA technology, better known as mRNA technology, made it possible to rapidly deploy a new vaccine during the COVID-19 pandemic — much earlier than would otherwise have been possible, saving ...
FDA reversal, patent relief, and mRESVIA risks show a commoditized market and lofty $20B valuation. See more here.
Aside from maybe high school biology classes, the first time many people heard of mRNA was during the pandemic because of the vital role MRNA technology played in COVID-19 vaccines. Subscribe to our ...
Personalized cancer vaccines are showing real clinical results, with melanoma patients on the mRNA-4157/pembrolizumab ...
WASHINGTON — The U.S. Food and Drug Administration is refusing to consider Moderna’s application for a new flu vaccine made with Nobel Prize-winning mRNA technology, the company announced Tuesday. The ...
Since the announcements by federal health authorities earlier this year that federal mRNA vaccine funding will be curtailed, a fierce debate has taken place around the future of mRNA-based vaccines ...
The FDA is reviewing the first mRNA flu vaccine for adults 50 and older. Learn how this technology could lead to faster and more effective shots.